Natera Inc. recently announced new findings from two clinical studies presented at the American Society of Hematology $(ASH)$ Annual Meeting. In a real-world analysis involving 144 patients with 14 subtypes of lymphoma, the Signatera test detected circulating tumor DNA (ctDNA) in 94% of pre-treatment samples. Results showed that ctDNA clearance during treatment was highly predictive of response to chimeric antigen receptor T-cell (CAR-T) therapy, and that rapid ctDNA clearance after one chemotherapy cycle correlated with better outcomes. Additionally, Signatera status at the end of first-line therapy was found to be highly prognostic for event-free survival, outperforming standard PET-CT assessments. In a separate HOVON study, conducted in collaboration with Foresight Diagnostics, the CLARITY ctDNA assay was used for longitudinal surveillance in 166 patients with diffuse large B-cell lymphoma. The study found that early molecular response, as detected by the assay, was associated with improved clinical outcomes. Following a negative ctDNA test, the probability of remaining relapse-free was 99% at six months and 97% at twelve months. Both studies underscore the potential of ctDNA assays for monitoring treatment response and long-term risk in lymphoma patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251209142398) on December 09, 2025, and is solely responsible for the information contained therein.
Comments